Regeneron Pharmaceuticals (REGN) Deferred Taxes (2013 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Deferred Taxes of $194.4 million for Q2 2026, up 43.79% year-over-year from $135.2 million in Q2 2025, and up 102.5% quarter-over-quarter from $96.0 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Deferred Taxes (2013 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Deferred Taxes history runs 14 years deep, the most recent figure standing at $194.4 million for Q2 2026.
- In Q2 2026, Deferred Taxes rose 43.79% year-over-year to $194.4 million; the TTM figure through Jun 2026 stood at $801.5 million (up 10.84% YoY), while the FY2025 annual figure was $785.4 million, up 3.71% from the prior year.
- Deferred Taxes for Q2 2026 stood at $194.4 million, up from $96.0 million in the prior quarter.
- The five-year high for Deferred Taxes was $286.3 million in Q4 2023, with the low at $85.7 million in Q3 2022.
- The 5-year median for Deferred Taxes is $192.4 million (2024), against an average of $189.8 million.
- The sharpest annual moves came in 2022 and 2024: Deferred Taxes jumped 2327.72% in 2022, then slumped 43.57% in 2024.
- Regeneron Pharmaceuticals' Deferred Taxes stood at $279.7 million in 2022, then advanced by 2.36% to $286.3 million in 2023, then fell by 2.13% to $280.2 million in 2024, then dropped by 17.02% to $232.5 million in 2025, then slipped by 16.39% to $194.4 million in 2026.
- Business Quant data shows REGN's Deferred Taxes at $194.4 million in Q2 2026, $96.0 million in Q1 2026, and $232.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 194.40 Mn |
| Mar 31, 2026 | 96.00 Mn |
| Dec 31, 2025 | 232.50 Mn |
| Sep 30, 2025 | 278.60 Mn |
| Jun 30, 2025 | 135.20 Mn |
| Mar 31, 2025 | 139.10 Mn |
| Dec 31, 2024 | 280.20 Mn |
| Sep 30, 2024 | 168.60 Mn |
| Jun 30, 2024 | 118.10 Mn |
| Mar 31, 2024 | 190.40 Mn |
| Dec 31, 2023 | 286.30 Mn |
| Sep 30, 2023 | 125.70 Mn |
| Jun 30, 2023 | 209.30 Mn |
| Mar 31, 2023 | 216.50 Mn |
| Dec 31, 2022 | 279.70 Mn |
| Sep 30, 2022 | 85.70 Mn |
| Jun 30, 2022 | 156.00 Mn |
| Mar 31, 2022 | 225.00 Mn |
| Dec 31, 2021 | 205.90 Mn |
| Sep 30, 2021 | -7.00 Mn |